Magenta Therapeutics Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Magenta Therapeutics last-minute Real Value cannot be determined due to lack of data. The latest price of Magenta Therapeutics is $0.0. Our model forecasts the value of Magenta Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.65, shares owned by insiders of 2.23 %, and Current Valuation of (32.66 M) as well as examining its technical indicators and probability of bankruptcy.
Magenta Therapeutics Total Value Analysis
Magenta Therapeutics is now anticipated to have valuation of (32.66 M) with market capitalization of 45.14 M, debt of 29.96 M, and cash on hands of 128.28 M. The negative valuation of Magenta Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Magenta Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(32.66 M) | 45.14 M | 29.96 M | 128.28 M |
Magenta Therapeutics Asset Utilization
One of the ways to look at asset utilization of Magenta is to check how much profit was generated for every dollar of assets it reports. Magenta Therapeutics secures a negative usage of assets of -0.29 %, losing $0.002885 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Magenta Therapeutics shows how discouraging it operates for each dollar spent on its assets.Magenta Therapeutics Ownership Allocation
Magenta Therapeutics maintains a total of 60.66 Million outstanding shares. Over half of Magenta Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Magenta Therapeutics Profitability Analysis
Net Loss for the year was (76.46 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Magenta Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Magenta Therapeutics and how it compares across the competition.
Magenta Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 59.4 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |